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Abstract
Importance—Trastuzumab is life-saving but is associated with symptomatic and asymptomatic 
left ventricular ejection fraction (LVEF) decline. Here we report the low cardiac toxicity of a non-
anthracycline and trastuzumab based treatment for patients with early stage HER2-positive breast 
cancer (BCA).
Objective—To determine the cardiac safety of paclitaxel and trastuzumab in patients with node-
negative, HER2-positive BCA.
Design—Enrollment occurred from October 2007 to September 2010, and patients received 
adjuvant paclitaxel for 12 weeks with trastuzumab, and trastuzumab was continued for one year. 
The median follow-up was 4.0 years.
Setting—Institutional practice
Participants—406 patients were enrolled. Eligibility included patients with ≤3 cm and node-
negative (N1mi allowed), HER2-positive BCA with baseline LVEF of ≥ 50%. Median age was 55 
years, 118 (29%) had hypertension, and 30 (7%) had diabetes.
Intervention—Treatment consisted of weekly paclitaxel (80 mg/m2) with trastuzumab (4mg/kg 
IV bolus → 2 mg/kg weekly) × 12 → 39 weeks of trastuzumab. LVEF was assessed at baseline, 
12 weeks, 6 months, and 1 year
Main Outcome Measures—Cardiac safety data, including grade 3-4 left ventricular systolic 
dysfunction (LVSD) and significant asymptomatic LVEF decline, as defined by study, were 
reported.
Results—Overall, 2 (0.5%) (95% CI: 0.1-1.8%) developed grade 3 LVSD and came off study. 
Thirteen (3.2%) (95% CI: 1.9-5.4%) had significant asymptomatic LVEF decline, 11 of whom 
completed study treatment. Median LVEF was 65%, 64%, 64%, and 64% at baseline 12 weeks, 6 
months, and 1 year, respectively.
Conclusion—Cardiac toxicity, manifested by symptomatic or asymptomatic LV dysfunction, 
from paclitaxel with trastuzumab, was low. Our findings suggest that LVEF monitoring during 
trastuzumab therapy without anthracyclines could be simplified for many individuals.
Trial Registration—Clinicaltrials.gov, NCT00542451
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Introduction
In the United States, breast cancer is the most common female cancer and the second most 
common cause of cancer death in women (1). Amplification or overexpression of the human 
epidermal growth factor receptor 2 (HER2/neu) oncogene is present in approximately 
20-25% of primary invasive breast cancers (2). Trastuzumab has demonstrated a significant 
improvement in outcomes of women with early stage breast cancer in key adjuvant trials, but 
most of these trials contained an anthracycline-based therapy followed by trastuzumab (with 
or without a taxane) in women with either node-positive or node-negative high-risk breast 
cancer (usually defined as tumor size >1 cm or >2 cm) (3-8). However, several studies from 
the pre-trastuzumab era suggest a higher risk of recurrence for patients with HER2-positive, 
node-negative tumors compared to those with HER2-negative tumors of the same size 
(9-11). Recent retrospective studies have demonstrated a benefit from the combination of 
chemotherapy and trastuzumab in those with node-negative disease and a time trend increase 
in the use of these agents (12-14).
The most significant toxicity of trastuzumab, especially following an anthracycline-based 
therapy, is symptomatic congestive heart failure (CHF) that has been reported on the order of 
0.9%-4% and significant asymptomatic decline ranging from 4%-19% in clinical trials 
(3,5-8). After the anthracycline phase, most of the events [symptomatic CHF and 
asymptomatic left ventricular ejection fraction decline (LVEF) decline] occurred during the 
period of trastuzumab administration (3-6, 15-18). Unlike cardiotoxicity associated with 
anthracyclines, cardiac dysfunction (LVEF decline) following trastuzumab therapy is not 
dose-related and is considered to be mostly reversible (19). Most previous clinical trials 
involving trastuzumab included patients who were exposed to anthracyclines where it is not 
clear how much the anthracyclines contributed to trastuzumab-mediated cardiac dysfunction. 
In order to reduce cardiac and non-cardiac toxicity with the hope of maintaining a high 
degree of efficacy, we conducted a trial of weekly paclitaxel with trastuzumab in patients 
with early stage HER2+ breast cancer. The overall study results have been previously 
reported and this manuscript highlights the detailed cardiac data that have been collected 
(20).
Methods
This was a phase 2 study across 14 centers of weekly paclitaxel with trastuzumab in patients 
with node-negative breast cancer (Figure 1). The study was approved by the institutional 
review board at each site. Written informed consent was obtained from each patient. Race, 
ethnicity, and sex were defined by each patient, to demonstrate the enrolled patient 
population (Table 1). The primary endpoint was disease-free survival (DFS). Grade 3 and 4 
left ventricular systolic dysfunction (LVSD), as defined by the National Cancer Institute 
Common Toxicity Criteria Adverse Events (NCI CTCAE) version 3.0, was a secondary 
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endpoint. Grade 3 LVSD is symptomatic CHF responsive to intervention and grade 4 LVSD 
is refractory CHF. Other adverse cardiac events were also classified per NCI CTCAE 
grading system version 3.0. This study protocol required longitudinal assessment of left 
ventricular systolic function using LVEF quantified by transthoracic echocardiogram 
(ECHO) or radionuclide multi-gated acquisition scan (MUGA) at baseline, 12 weeks, 6 
months, and 1 year after starting protocol specified therapy. Patients who went off treatment 
early due to CHF were also required to have follow-up LVEF assessments 3, 6, and 12 
months after the CHF event.
The analysis population was defined as all patients who received any amount of protocol 
therapy. Diagnosis of grade 3-4 LVSD (symptomatic CHF) during protocol therapy required 
cessation of trastuzumab therapy. For these patients, we reported the registration date, 
protocol therapy starting date, off-treatment date, number of cycles administered, and LVEF 
percentages. Trastuzumab was interrupted for asymptomatic declines in LVEF within the 
following categories: 1) a decrease of 10-15 percentage points from a baseline LVEF that 
was less than the local lower limit of normal (LLN) for LVEF, or 2) a decrease ≥16 
percentage points from a baseline LVEF that was greater than or equal to local LLN for 
LVEF (eTable 1). All patients with interval development of either symptomatic or 
asymptomatic LVSD described above requiring interruption of trastuzumab underwent 
repeat LVEF assessment using the same modality after an interval of 4 weeks. If the LVEF 
did not recover to a “continue” category as defined by study guidelines (eTable 1) and if two 
consecutive “holds” were required, then the patient would be withdrawn from study 
treatment. Investigators were strongly urged to schedule MUGA scans or ECHOs at the 
same radiology facility where the patient’s baseline scan was done, and we used the baseline 
LLN to compare to LVEF assessed at 12 weeks, 6 months, and 1 year. The incidence of 
grade 3-4 LVSD was determined with the 95% confidence interval (CI). The median LVEF 
for each time point and proportion of patients within each category of LVSD are presented.
Statistical Analysis
The planned sample size of 400 was based on the primary endpoint of disease-free survival. 
The statistical design and sample size considerations have been described elsewhere (20). 
The incidence of LVSD and asymptomatic LVEF decline were secondary endpoints. For this 
analysis, the incidence of LVSD and asymptomatic LVEF decline were analyzed as binary 
outcomes. Rates of LVSD and asymptomatic LVEF decline and 95% confidence intervals 
(CI) were calculated using Wilson’s method. With a planned sample size of 400 patients, the 
estimated half-width of the 95% Wilson confidence interval was 0.5%, 1.1%, 14%, 1.7%, 
2.0% and 2.2% with 0, 4, 8, 12, 16, and 20 cases of LVSD observed.
To explore the association between baseline characteristics and occurrence of cardiac 
toxicity, relative risks (RR) and 95% confidence intervals (CI) were calculated using robust 
variance estimates (21-22). Statistical analyses were performed using SAS® 9.3 and R 
version 2.6.1.
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Eligible patients had HER2 IHC 3+ or FISH-amplified (ratio ≥ 2.0) breast cancer, with 
node-negative breast cancer and a tumor size of ≤ 3 cm, were enrolled. Patients with a 
micrometastasis in a lymph node were later allowed with study amendment on May 19, 
2009. Patients with a baseline LVEF < 50%, history of myocardial infarction (MI), CHF, 
uncontrolled hypertension (systolic blood pressure of > 200 mmHg or diastolic blood 
pressure of > 100 mmHg), or hemodynamically significant pericardial effusion were 
excluded from this study.
Treatment
Treatment consisted of weekly paclitaxel (80 mg/m2) administered intravenously (IV) 
concurrently with trastuzumab (4mg/kg IV bolus followed by 2 mg/kg weekly) × 12 
followed by trastuzumab monotherapy × 39 weeks. During the monotherapy phase, 
trastuzumab could be given weekly or every 3 weeks (6 mg/kg) (Figure 1). Radiation and 
hormonal therapy were administered per standard guidelines after completion of the 12 
weeks of chemotherapy.
Results
From October 9, 2007 to September 3, 2010, 410 patients enrolled and 406 started protocol 
therapy. All 406 patients completed treatment as of September 8, 2011. The median follow-
up was 4.0 years. The median age was 55 years of age, and 118 (29%) and 30 (7%) patients 
had a history of hypertension and diabetes, respectively (Table 1). The majority of patients 
with hypertension (84%) and diabetes (83%) were at least 50 years of age (Table 2). There 
were 356 (88%) patients who completed about a year of protocol therapy and 50 (12%) who 
did not. The 50 patients were taken off study for the following reasons: 2 for grade 3 LVSD, 
2 for persistent grade 2 LVSD, 1 for grade 3 arrhythmia, 1 for grade 3 sinus tachycardia, 1 
for grade 2 palpitations, 42 for non-cardiac reasons, and 1 for an unknown reason. Overall, 7 
(1.7%) patients discontinued protocol treatment for all cardiovascular reasons but only 4 
(1.0%) patients discontinued due to LVSD (95% CI 0.3%-2.5%).
Changes in Left Ventricular Ejection Fraction
Baseline LVEF values were between 50%-55% in 40 (10%), and > 55% in 366 (90%) 
patients (eTable 2). Of the 40 patients with baseline LVEF of ≤ 55%, 26 (65%) were at least 
50 years of age. Overall, the majority of patients had a minimal decline in LVEF of < 10% 
(84%, 80% and 74%), and only a minority of patients had a decline in LVEF to 10-15% 
(7%, 9%, and 9%) and ≥ 16% (< 1%, 1%, and 2%) from baseline at 12 weeks, 6 months, and 
1 year, respectively. The median LVEF values were well preserved throughout treatment as 
65% (50%-81%), 64% (45%-81%), 64% (45%-83%), and 64% (41%-90%) at baseline, 12 
weeks, 6 months, and 1 year, respectively (Table 3).
Symptomatic Left Ventricular Systolic Dysfunction
Out of 406 patients who started protocol therapy, 2 patients (#257 and #309) developed 
grade 3 LVSD (0.5%, 95% CI: 0.1%-1.8%). Patient #257 was a 67 year-old female on 
medications for hyperlipidemia upon study entry who developed symptomatic CHF at 11 
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months after starting treatment. Her LVEF assessments were as follows: 55% at baseline, 
54% at 12 weeks, 60% at 6 months, and 37% at 11 months. She did not resume trastuzumab 
per study stipulation. Subsequent treatment with lisinopril achieved full resolution of CHF 
symptoms and a restoration of LVEF to normal: 60% at 16 months and 66% at 27 months 
(eTable 3eFigure). Patient #309 was a 56 year-old female on a beta-blocker for a diagnosis 
of arrhythmogenic right ventricular dysplasia. Her LVEF was 66% at baseline and 61% at 12 
weeks, and it declined to 50% at 6 months, which coincided with the onset of symptoms of 
CHF. Trastuzumab was terminated. Medical management with a regimen of furosemide, 
ramipril, and carvedilol was initiated, and she became asymptomatic with an improvement 
in subsequent LVEF assessments: 51% at 7 months, 54% at 8 months, and 56% at 18 months 
(eTable 3, eFigure). Both patients were medically managed by their cardiologists for CHF. 
Overall, these 2 patients had at least 2 potential risk factors for cardiac dysfunction. Both 
patients were older than 50 years of age. Patient #257 also had a baseline LVEF of only 
55%, and patient #309 had arrhythmogenic right ventricular dysplasia. This is due to fatty 
infiltration of the RV, and most of these patients will have LV involvement over time 
resulting in bi-ventricular failure.
Incidence of Asymptomatic Decrease in Left Ventricular Ejection Fraction
Overall, 13 (3.2%) (95% CI: 1.9-5.4%) of patients experienced an asymptomatic LVEF 
decline significant enough to require trastuzumab interruption as per study criteria (eTable 
3). Two patients (# 168 and # 325) discontinued protocol therapy. Patient # 254 had 
significant asymptomatic LVEF decline that did not recover during the study timeframe 
(within 4 weeks). However, she was not taken off study and trastuzumab was continued 
(study violation). Of the 3 patients with “persistent” (lasting for at least 4 weeks) 
asymptomatic LVEF decline (grade 2 LVSD), two (# 168 and # 325) had at least 2 potential 
risk factors (at least 50 years of age and baseline LVEF of only 55%); patient # 168 also had 
hypertension and diabetes. Patient # 168 was on cardiac medications (amlodipine, atenolol) 
at baseline for hypertension and did not have additional medications at time of trastuzumab 
cessation; patient # 325 had cardiac medications (lisinopril, losartan, carvedilol) added 
(eTable 3).
In the remaining 10 patients with significant asymptomatic LVEF decline during treatment, 
6 had already completed one year of therapy when a significant asymptomatic LVEF decline 
occurred at the end of treatment (# 27, # 50, # 227, # 279, # 338, and # 360), and 2 patients 
had cardiac medications added (# 279 and # 360). As these patients completed therapy 
already, any follow-up LVEF monitoring was at the physician’s discretion. The other 4 
patients (# 71, # 97, # 147, and # 173) experienced significant asymptomatic LVEF 
decrement and recovered appropriately before completing one year of therapy; only 1 patient 
(# 173) had cardiac medication added but other 3 did not. In these 10 patients only 3 had 2 
cardiovascular risk factors (at least 50 years of age and hypertension) (# 50, # 147, and # 
173), and 2 patients were on anti-hypertensive medication at baseline and 1 was not. Of note 
in the 10 patients, all but 1 patient had LVEF > 55%. Overall, in these 13 (3.2%) patients 
with significant asymptomatic LVEF decline, only 5 had at least 2 cardiovascular risk factors 
and notably only 3 had LVEF of 55%. We performed an exploratory analysis to assess the 
relationship between baseline characteristics and cardiac outcomes and there appeared to be 
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a correlation between a low baseline LVEF of ≤ 55% and higher incidence of significant 
asymptomatic LVEF decline or symptomatic LVSD (RR 0.30, 95% CI: 0.10-0.90)(p = 0.05) 
(Table 4).
Discussion
This regimen of paclitaxel and trastuzumab (without an anthracycline) has already 
demonstrated exceptional outcomes with 3-year DFS exceeding 98.7% (20). In this analysis 
we also demonstrate that it is well-tolerated, with incidence of symptomatic CHF of only 
0.5% (95% CI: 0.1-1.8%). This is consistent with the data from BCIRG 006 and the phase II 
trial by Jones et al on docetaxel and cyclophosphamide with trastuzumab (7, 23). The 
incidence of grade 3-4 LVSD for both studies was 0.4% with a non-anthracycline taxane/
trastuzumab combination (5, 23). In this study, the two patients who developed grade 3 
LVSD had at least 2 cardiovascular risk factors and experienced CHF during active therapy 
at 6 and 11 months, respectively, with subsequent recovery. Only 13 (3.2%) (95% CI: 
1.9-5.4%) of 406 patients demonstrated a significant asymptomatic decline in LVEF 
requiring trastuzumab interruption per protocol. Of these 13 patients, 3 had “persistent” 
LVEF decline; 2 patients were removed from study and 1 continued therapy (study 
violation). The remaining 10 patients completed trastuzumab as planned. In these 13 
patients, 5 had at least 2 cardiovascular risk factors.
These results compared favorably to the combined analysis of NSABP B-31/N9831, in 
which 14.2% of patients did not complete one year of trastuzumab due to significant 
asymptomatic LVEF deterioration (3). The low incidence of LVEF decline in our study was 
most likely attributable to the absence of the anthracycline. In addition, over the last decade, 
there has been a higher threshold to stop trastuzumab as a result to asymptomatic LV 
dysfunction given the growing appreciation of the benefits of trastuzumab therapy and 
collaboration between cardiologists and oncologists (24). In our study, 88% of patients 
completed one year of therapy, which included the patients who resumed therapy after a 
temporary interruption for asymptomatic LVEF decline. This was favorable when compared 
to the phase II study by Jones et al in which only 82% of patient completed the full year of 
therapy (23).
Previous data suggest that late cardiac toxicity from trastuzumab therapy is rare in oncology 
clinical trials. Seven and eight year follow-up data from the NSABP B-31 and HERA trials, 
respectively, described no increase in the cardiac event (NYHA Class III-IV heart failure/
cardiac death) rate, with events occurring mainly during active therapy (6, 25). In addition, 
cardiac events reported for two trials of dose-dense chemotherapy with anti-HER2 agents 
occurred mainly during active therapy, with 5-year and 7-year follow-up data, respectively 
(18). When extrapolating these data to the current study with a median follow-up of 4.0 
years, it is likely that the low incidence of grade 3 LVSD of 0.5% with paclitaxel and 
trastuzumab will not change over time with a longer follow-up.
In contrast, recent claims-based reports have shown heart failure/cardiomyopathy rates 
exceeded those reported by other prospective studies with long-term follow-up durations (6, 
18, 25). For example, Bowles et al conducted a population-based retrospective cohort study 
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of 12,500 women with invasive breast cancer who were treated with no chemotherapy, 
anthracycline, trastuzumab, anthracycline + trastuzumab, or other chemotherapies. In this 
study, only 0.9% of patients received trastuzumab (without an anthracycline). At 1, 3, and 5 
years, the respective rates of heart failure/cardiomyopathy were 3.6%, 7.8%, and 12.1% with 
trastuzumab (without an anthracycline) (26). These findings were similar to those reported 
in papers by Chen et al, Chavez-MacGregor and colleagues, and Ezaz et al (27-29). The 
patient populations in these retrospective studies were much older with the mean ages 
ranging from 60-76 years old (26-29). The higher rates in these retrospective studies, when 
compared to well-designed prospective trials, could be due to an overestimation of the true 
risk of cardiac toxicity in claims-based studies and/or that the patients in prospective clinical 
trials were healthier and younger by selection. Finally, retrospective claims-based data were 
also limited due to a lack of rigorous adjudication of events.
Risk factors associated with trastuzumab related cardiac toxicity include anthracycline 
exposure and age ≥ 50 years (25, 31-34). Our exploratory analysis suggested an association 
between low baseline LVEF of ≤ 55% and incidence of asymptomatic LVEF decline and 
symptomatic LVSD. In addition, multivariate analyses identified borderline low LVEF of < 
55%, hypertension, and high body mass index as predisposing risk factors for trastuzumab-
induced cardiotoxicity, while influences of diabetes, valvular heart disease, and coronary 
artery disease were not statistically significant (25, 32, 34-35). Concurrent trastuzumab with 
radiation does not increase cardiac toxicity (25, 34, 36). In our study of 406 patients, 40 
(10%) had baseline LVEF of ≤ 55%; 26 (6%) had baseline LVEF of ≤ 55% and were ≥ 50 
years of age. Additionally, 118 (29%) had a history of hypertension, 30 (7%) had diabetes, 
and the majority of patients with hypertension (84%) and diabetes (83%) were at least 50 
years of age. Given the low incidence of cardiac dysfunction in our study, where patients did 
not receive an anthracycline, perhaps serial monitoring may be reserved for patients 
considered at a higher risk of developing cardiotoxicity and those with signs and symptoms 
of CHF or other cardiac symptoms. If this approach to screening was implemented in this 
study, many LVEF assessments would have been avoided for the majority of asymptomatic 
patients with baseline LVEF > 55% without coexisting cardiovascular risk factors. The 
extent to which such rationalized LVEF surveillance might reduce interruption of 
trastuzumab, reduce cost, and impact upon cardiovascular and cancer prognoses requires 
investigation. Moreover, we advocate for closer collaboration between cardiologists and 
oncologists in determining the best strategies in identifying patients who are at risk of 
developing heart failure such that the patient can complete the course of trastuzumab therapy 
without interruption.
This study had some limitations. First, LVEF quantifications by ECHO or MUGA in this 
study did not follow a standard protocol and a core lab was not used for analyses; thus, data 
on inter- and intra-observed variability and reproducibility of LVEF reports in this study 
were lacking. However, this limitation was common to many chemotherapy trials that 
included cardiovascular safety end-points. Second, certain patient groups that were 
considered at higher risk for trastuzumab-associated cardiotoxicity, such as those with a 
history of MI or CHF, were excluded from this study. As such, study findings and 
recommendations for a reduced number of LVEF assessments cannot be generalized to such 
patients. Third, it is increasingly clear from emerging cardiac literature that LVEF may not 
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be the best marker of cardiac contractility (37). Fourth, data for certain cardiovascular risk 
factors such as hyperlipidemia, cerebrovascular disease, and prior coronary 
revascularizations were not consistently collected. Fifth, management of deteriorations in 
LVEF during treatment was directed at the physician discretion; variation in management 
likely influenced likelihood of recovery in LVEF.
In conclusion, the incidence of symptomatic and asymptomatic deteriorations in LVEF 
during treatment with paclitaxel and trastuzumab was low, 0.5% and 3.2%, respectively. The 
favorable cardiovascular safety profile of trastuzumab in this non-anthracycline setting 
suggests that baseline LVEF assessment may be sufficient for the majority of patients, with 
serial LVEF assessments reserved for patients considered at a higher risk for cardiotoxicity. 
A prospective trial to include a uniform assessment and management of cardiovascular risk 
factors and a central review of LVEF data in patients receiving a non-anthracycline regimen 
with anti-HER2 therapy will be needed to help further define which patients may have less 
intensive LVEF monitoring.
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Figure. 1. Schema Phase II Study of Paclitaxel + Trastuzumab N =406
T=paclitaxel weekly at 80 mg/m2
H=trastuzumab 4 mg/kg load → 2 mg/kg weekly during TH phase → 6 mg/kg
q 3 weeks (or 2 mg/kg weekly) during H monotherapy
Dang et al. Page 13






























Median Age (Range) 55 (24-85) .
Sex
 Male 1 <1
 Female 405 100
Race
 White 351 86
 African American 28 7
 Asian 11 3
 Other 16 4
Ethnicity
 Hispanic or latino 9 2
 Non-Hispanic 374 92
 Ethnicity Not Known 23 6
History of Hypertension
 Yes 118 29
 No 288 71
History of Diabetes
 Yes 30 7
 No 376 93
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Table 2
Distribution of Age in Patients with HTN and DM
Age (years) All patients Patients with HTN Patients with DM
N 406 118 30
Median (Range) 55 (24-85) 61 (40-85) 59 (40-76)
Age Group (years) N (%) N (%) N (%)
<50 132 (33) 19 (16) 5 (17)
50-59 137 (34) 32 (27) 10 (33)
60-69 96 (24) 45 (38) 11 (37)
70+ 41 (10) 22 (19) 4 (13)
HTN=hypertension; DM=diabetes
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